Radiotherapy developer RayzeBio has spun off a China-focused subsidiary called Ablaze with series A funding from investors also including Nan Fung.

China-headquartered radiopharmaceutical therapy developer Ablaze Pharmaceuticals emerged from stealth yesterday with $75m in series A funding from investors including Rayz Investments, a vehicle for radiopharmaceutical treatment developer RayzeBio.

Vivo Capital and AdvanTech Capital co-led the round, which also featured Nan Fung Life Sciences, a subsidiary of property developer Nan Fung, and its Pivotal BioVenture Partners China fund, as well as VenBio Partners, Samsara BioCapital and Venrock Healthcare Capital Partners.

Ablaze was formed earlier this year by US-headquartered RayzeBio to develop…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn